达立通联合马来酸曲美布汀治疗便秘型肠易激综合征的临床观察  

Clinical observation of Darliton combined with Trimebutine Maleate in the treatment of Constipation irritable bowel syndrome

作　　者：冯慧玲 李芳伶[1] 张亮 吴君伟[1] 肖林林[1] 谢宁生[1] Feng Huiling;Li Fangling;Zhang Liang;Wu Junwei;Xiao Linlin;Xie Ningsheng(Ganzhou People's Hospital,Ganzhou,Jiangxi,341000)

机构地区：[1]江西省赣州市人民医院,江西赣州341000

出　　处：《首都食品与医药》2022年第9期55-57,共3页Capital Food Medicine

基　　金：江西省赣州市科技局指导性科技计划项目(项目编号:GZ2020ZSF141)。

摘　　要：目的探究达立通联合马来酸曲美布汀用于治疗便秘型肠易激综合征的临床价值.方法选择2020年6月-2021年5月就诊于赣州市人民医院的82例确诊为IBS-C的患者,以随机数字表法将其分成观察组和对照组各41例.对照组患者采用马来酸曲美布汀单药治疗的方案,观察组则在对照组的基础上加用达立通颗粒治疗,两组均连续治疗1个月.观察两组患者治疗后的临床疗效、治疗前后大便性状分级、排便困难程度评分、排便时间以及治疗期间发生的不良反应情况.结果观察组治疗后的临床总有效率为92.68%,高于对照组的80.49%(P<0.05);观察组治疗后大便Bristol分型评分高于对照组,排便困难程度评分均低于对照组,排便时间则显著短于对照组(P<0.05);两组治疗期间不良反应的发生情况比较,无显著性差异(P>0.05).结论达立通联合马来酸曲美布汀的联合治疗方案用于IBS-C患者疗效显著,可以在不增加不良反应的前提下,提高临床治疗总有效率,改善患者大便性状和排便困难程度,缩短排便时间.Objective To explore the clinical value of Daritone combined with trimebutine maleate in the treatment of constipation irritable bowel syndrome.Methods A total of 82 patients diagnosed with IBS-C who visited our hospital from June 2020 to May 2021 were selected and divided into observation group and control group by random number table method,41 cases in each group.The patients in the control group were treated with trimebutine maleate monotherapy,and the patients in the observation group were treated with Dalitong granules on the basis of the control group.Both groups were treated for 1 month continuously.The clinical curative effect,stool character classification,defecation difficulty score,defecation tinie,and adverse reactions during treatment were observed in the two groups of patients before and after treatment.Resu Its After treatment,the total clinical effective rate in the observation group was 92.68%higher than that in the control group(80.49%)(P<0.05).After treatment,the stool Bristol classification score of the observation group was higher than that of the control group,the score of defecation difficulty was lower than that of the control group,and the defecation time was significantly shorter than that of the control groups(P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups during treatment(P>0.05).Conclusion The combination therapy of Daritone+Trimebutine Maleate is effective in patients with IBS-C,which can improve the total effective rate of clinical treatmentsmprove the stool characteristics and difficulty of defecation,shorten bowel movements without increasing adverse reactions.

关 键 词：达立通 马来酸曲美布汀 便秘型肠易激综合征 大便性状 

分 类 号：R975[医药卫生—药品]